title: The usefulness of arbekacin compared to vancomycin.
abstract: The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin group (32.9%) compared to the arbekacin group (15.1%) (p=0.019). Arbekacin was not inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment.
authors: The Department of Pharmacy, Chonbuk National University Hospital, and The Department of Preventive Medicine, Chonbuk National University Medical School, Jeonju, Jeonbuk, South Korea.
authors: J-H
authors: JH
authors: Hwang
authors: J-H
authors: JH
authors: Lee
authors: M-K
authors: MK
authors: Moon
authors: J-S
authors: JS
authors: Kim
authors: K-S
authors: KS
authors: Won
authors: C-S
authors: CS
authors: Lee
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D008875:Middle Aged; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D003982:Dibekacin; D014640:Vancomycin; C031986:arbekacin